Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Ophthalmologists

Articles with lock require a subscription to GLG News | Request a free trial
March 5, 2008
New molecule for the treatment of rheumatoid arthritis with minor toxicity.
Analysis of: Glenmark’s molecule for Rheumatoid Arthritis - GRC 4039 | www.pipelinereview.com
Author: GLG Expert Contributor
1. Rheumatoid arthritis as an invalidating disease (1% population). 2. Anti TNF-α agents. 3. Clinical trial for inflammatory disorders by Glenmark.
March 5, 2008
Decreasing the risk of complications in the treatment of wet AMD.
Analysis of: MacuSight Announces Positive Preliminary Results From Phase 1 Study of Sirolimus in Wet Age-Related Macular Degeneration | pharmalive.com
Author: GLG Expert Contributor
1. Wet AMD. 2. Macular edema. 3. Intravitreal injection.
March 5, 2008
Choosing the best treatment for wet AMD.
Analysis of: Comparison of AMD Treatments Trials (CATT): Lucentis — Avastin Trial | www.pipelinereview.com
Author: GLG Expert Contributor
1. Lucentis. 2. Avastin. 3. Cost.
March 5, 2008
Keeping the privacy of health data.
Analysis of: Google to store patients' health records | news.yahoo.com
Author: GLG Expert Contributor
1. Internet. 2. Medical records. 3. Privacy.
February 29, 2008
Effect of Punctal Plugs in Patients with Low Refractive Errors Considering Refractive Surgery
Analysis of: Effect of Punctal Plugs in Patients with Low Refractive Errors Considering Refractive Surgery | www.journalofrefractivesurgery.com
Author: GLG Expert Contributor
This was a retrospective clinical study of 21 eyes from 12 patients who identified themselves as being dissatisfied with their visual acuity and were interested either in initial or enhancement refractive surgery in order to improve their acuity. Uncorrected visual acuity was documented in each eye....
February 28, 2008
Sirolimus (Macusight) is Latest Player to Enter the AMD Market
Analysis of: MacuSight Announces Positive Preliminary Results From Phase 1 Study of Sirolimus in Wet Age-Related Macular Degeneration | pharmalive.com
Author: GLG Expert Contributor
Sicrolimus is a novel agent that has a broad range of activities that is entering the Ophthalmic Arena.  Phase I Data has shown its safety profile in treating two large markets: Age Related Macular Degeneration and Diabetic Macular Edema.  Given its success in cardiology, it is a promising...
February 28, 2008
Zylet (Bausch & Lomb) as as good and safer than Tobradex (ACL) for Blepharitis.
Analysis of: Bausch & Lomb Announces Positive Clinical Results for Zylet in a Comparison of Safety and Efficacy with Tobradex in the Treatment of Blepharokeratoconjunctivitis | pharmalive.com
Author: GLG Expert Contributor
This study shows that Bausch and Lomb's Zylet is as good and safer than Alcon's Tobradex for the management of Blepharitis.  Blepharitis is a large problem affecting many patients.  This could be a large market opportunity.
February 28, 2008
Biovitrum's BVT.28949 Glaucoma Medication Results are Disappointing
Analysis of: Biovitrum has Completed an Exploratory Clinical Phase II Study in Glaucoma | www.pipelinereview.com
Author: GLG Expert Contributor
Biovitrum reports Phase II results of its new glaucoma medication. Although the mechanism of action of this glaucoma drug is novel and targets the site of disease in glaucoma, its clinical results are very disappointing.  A 10% reduction in intraocular pressure is not enough to make a clinical...
February 28, 2008
CATT Trial will Likely sink Genetech's (DNA) Lucentis for AMD Treatment.
Analysis of: Comparison of AMD Treatments Trials (CATT): Lucentis — Avastin Trial | www.pipelinereview.com
Author: GLG Expert Contributor
The CATT Trial will prospectively compare lucentis and avastin head to head in the management of Age Related Macular Degeneration.  Lucentis costs 40X more than Avastin for ocular dosing; and many suspect that they both are similiar in efficacy.  If CATT confirms this, it sink Lucentis Sales...
February 19, 2008
New promising agent for glaucoma treatment
Analysis of: Biovitrum has Completed an Exploratory Clinical Phase II Study in Glaucoma | www.pipelinereview.com
Author: GLG Expert Contributor
1. Glaucoma therapy 2. IOP reduction 3. Combined therapy

Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 Next21 to 30 of 158

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-05T01:45:24.617